ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate

Source: BenzingaBut beneath the surface, a powerful positioning imbalance is quietly building.40% Short Interest Creates A Structural Pressure PointMore than 135 million ImmunityBio shares are currently sold short, representing over 40% of its float. That's an unusually high level — and one that creates structural risk for bearish investors if the stock continues rising.Short sellers eventually must buy back shares to close positions. When prices rise rapidly, that process can accelerate, forcing additional ...